These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35697709)

  • 1. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.
    Tsuboi T; Satake Y; Hiraga K; Yokoi K; Hattori M; Suzuki M; Hara K; Ramirez-Zamora A; Okun MS; Katsuno M
    NPJ Parkinsons Dis; 2022 Jun; 8(1):75. PubMed ID: 35697709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
    Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription Pattern of Monoamine Oxidase B Inhibitors Combined with Levodopa: A Retrospective Observational Analysis of Italian Healthcare Administrative Databases.
    Ronconi G; Calabria S; Piccinni C; Dondi L; Pedrini A; Esposito I; Addesi A; Sambati L; Martini N
    Drugs Real World Outcomes; 2022 Sep; 9(3):391-401. PubMed ID: 35696024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease.
    Okano M; Takahata K; Sugimoto J; Muraoka S
    Front Behav Neurosci; 2019; 13():176. PubMed ID: 31427934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
    Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
    J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase B inhibitors for early Parkinson's disease.
    Macleod AD; Counsell CE; Ives N; Stowe R
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
    Gallagher DA; Schrag A
    CNS Drugs; 2008; 22(7):563-86. PubMed ID: 18547126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
    Parambi DGT
    Comb Chem High Throughput Screen; 2020; 23(9):847-861. PubMed ID: 32238135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
    Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
    Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.